Spectral MD Holdings Ltd. has delivered stark evidence of the need for its Deepview wound imaging system, in a study showing that medics in emergency rooms making initial judgments on the severity of burns were accurate only in 74% of cases. The critical feature is the depth of a burn.
International research project Multicentre Epilepsy Lesion Detection (MELD), led by University College London, has developed artificial intelligence software that can identify minute brain anomalies that lead to epilepsy seizures. These anomalies, known as focal cortical dysplasia, can often be treated with surgery but are difficult to visualize on an MRI.
The question of whether an artificial intelligence (AI) algorithm should enjoy the status of an inventor has been making the rounds in various nations, but the U.S. Court of Appeals for the Federal Circuit has rejected the notion based on a plain reading of the statute. The court said that the statute is unambiguous in that only natural persons can claim inventorship, but the question will be appealed to the Supreme Court, which will have an opportunity to put this debate to rest.
Shanghai Aitrox Technology Co. Ltd. (Fosun Aitrox) completed strategic financing of over ¥100 million (US$14.8 million) to develop its pipelines in artificial intelligence (AI)-aided diagnosis platforms. This financing was led by Shanghai Fosun Pharmaceutical (Group) Co. Ltd. and Sinopharm-CICC (Shanghai) Private Equity Investment Management Co. Ltd.
Recent U.S. FDA actions could transform decades of prostate cancer care. Two companies focused on prostate cancer received good news from the FDA for their artificial intelligence (AI)-driven software. Bot Image Inc. gained FDA clearance for its medical device computer-aided detection and diagnostic tool, Prostatid. The agency also provided FDA investigational device exemption for Avenda Health Inc.’s Focalpoint ablation system that enables more accurate mapping of a patient’s prostate cancer for better surgical results.
The European Commission launched a new research initiative with $10 million from Horizon Europe, the E.U.’s research and innovation program, to create a cutting-edge decision-making tool to help clinicians and patients select the best lung cancer treatment based on each patient’s specific needs and circumstances. The I3Lung initiative brings together 16 international partners from Germany, Belgium, Denmark, Italy Sweden, Switzerland, the U.S. and Israel.
Cognetivity Neurosciences Ltd. is making progress in promoting its cognitive assessment tool as the brain health equivalent of a blood pressure check, following feedback from clinicians indicating the test could have broad applicability.
Infervision Medical Technology Co. Ltd. received approval from China’s NMPA for its radiological computer-assisted triage and notification software device Inferread CT Stroke. This is the first class III approval that the firm obtained in the cerebro-cardiovascular field. Class III approvals are for high-risk medical devices.
Medtronic plc has entered a strategic collaboration with Cathworks Ltd. to expand the reach of Cathworks’ artificial intelligence (AI) guidance system for coronary artery disease management. Medtronic will invest up to $75 million and immediately begin co-promotion of the Ffrangio system on the U.S., European and Japanese market. As part of a separate agreement, Dublin-headquartered Medtronic will have the option to acquire Cathworks once certain undisclosed milestones are met.
Clinical analytics company Medial Earlysign Ltd. is expanding an existing partnership with Roche Holding AG to commercialize an artificial intelligence (AI) solution for the early detection of lung cancer. The companies originally signed an agreement in September to develop a personalized health solution for early detection of gastric cancer. The goal of the new collaboration is to develop Earlysign’s Lungflag software, which uses machine learning to identify patients at risk of developing lung cancer.
RSS
